Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Aug. 31, 2019	Nov. 26, 2019	Feb. 28, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-K
Document Period End Date	Aug. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		17,398,112
Entity Public Float			$ 42,511,402
Entity File Number	000-50298
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

Consolidated Balance Sheets - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 3,329	$ 4,996
Short-term deposits (note 2)	25,252	20,875
Marketable securities (note 3)	3,701	4,592
Prepaid expenses and other current assets	1,042	574
Total current assets	33,324	31,037
LONG-TERM ASSETS:
Long-term deposits and investment (note 4)	1	13,542
Marketable securities (note 3)	1,295	2,785
Amounts funded in respect of employee rights upon retirement	19	16
Property and equipment, net	24	17
Total long-term assets	1,339	16,360
Total assets	34,663	47,397
CURRENT LIABILITIES:
Accounts payable and accrued expenses (note 5)	2,541	2,058
Deferred revenues	2,703	2,449
Payable to related parties (note 11c)	64	46
Total current liabilities	5,308	4,553
LONG-TERM LIABILITIES:
Deferred revenues	9,658	11,388
Employee rights upon retirement	22	20
Provision for uncertain tax position (note 10f)	11	11
Other liabilities	271	313
Total long-term liabilities	9,962	11,732
COMMITMENTS (note 6)
STOCKHOLDERS' EQUITY:
Common stock, $ 0.012 par value (30,000,000 authorized shares as of August 31, 2019 and 2018; 17,383,359 and 17,369,875 shares issued and outstanding as of August 31, 2019 and 2018, respectively)	208	207
Additional paid-in capital	100,288	99,426
Accumulated other comprehensive income		702
Accumulated deficit	(81,103)	(69,223)
Total stockholders' equity	19,393	31,112
Total liabilities and stockholders' equity	$ 34,663	$ 47,397

Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2019	Aug. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	17,383,359	17,369,875
Common stock, shares outstanding	17,383,359	17,369,875

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Income Statement [Abstract]
REVENUES	$ 2,703	$ 2,449	$ 2,456
COST OF REVENUES (INCOME) (note 6g)	90	(86)	187
RESEARCH AND DEVELOPMENT EXPENSES	13,522	11,979	10,281
GENERAL AND ADMINISTRATIVE EXPENSES	3,722	4,083	2,759
OPERATING LOSS	14,631	13,527	10,771
FINANCIAL INCOME (note 9a)	1,061	903	792
FINANCIAL EXPENSES (note 9b)	485	103	101
LOSS BEFORE TAXES ON INCOME	14,055	12,727	10,080
TAXES ON INCOME (note 10d)	300		400
NET LOSS FOR THE YEAR	14,355	12,727	10,480
UNREALIZED INCOME ON AVAILABLE FOR SALE SECURITIES		(301)	(295)
TOTAL OTHER COMPREHENSIVE INCOME		(301)	(295)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 14,355	$ 12,426	$ 10,185
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.82	$ 0.86	$ 0.79
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	17,454,489	14,882,356	13,309,372

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit	Total
BALANCE at Aug. 31, 2016	$ 157	$ 71,943	$ 106	$ (46,016)	$ 26,190
BALANCE, Shares at Aug. 31, 2016	13,183
SHARES ISSUED FOR SERVICES		72			72
SHARES ISSUED FOR SERVICES, Shares	10
ISSUANCE OF COMMON STOCK, NET		25			25
ISSUANCE OF COMMON STOCK, NET, Shares	3
EXERCISE OF WARRANTS AND OPTIONS	$ 4	1,557			1,561
EXERCISE OF WARRANTS AND OPTIONS, Shares	313
STOCK-BASED COMPENSATION	$ 2	1,573			1,575
STOCK-BASED COMPENSATION, Shares	159
NET LOSS				(10,480)	(10,480)
OTHER COMPREHENSIVE INCOME			295		295
BALANCE at Aug. 31, 2017	$ 163	75,170	401	(56,496)	19,238
BALANCE, Shares at Aug. 31, 2017	13,668
ISSUANCE OF COMMON STOCK AND WARRANTS, NET	$ 42	21,615			21,657
ISSUANCE OF COMMON STOCK AND WARRANTS, NET, shares	3,466
SHARES ISSUED FOR SERVICES		99			99
SHARES ISSUED FOR SERVICES, Shares	14
EXERCISE OF WARRANTS AND OPTIONS	$ 2	995			997
EXERCISE OF WARRANTS AND OPTIONS, Shares	189
STOCK-BASED COMPENSATION		1,547			1,547
STOCK-BASED COMPENSATION, Shares	32
NET LOSS				(12,727)	(12,727)
OTHER COMPREHENSIVE INCOME			301		301
BALANCE at Aug. 31, 2018	$ 207	99,426	702	(69,223)	31,112
BALANCE, Shares at Aug. 31, 2018	17,369
INITIAL ADOPTION OF ASU 2016-01			(702)	702	0
INITIAL ADOPTION OF ASC 606				1,773	1,773
SHARES ISSUED FOR SERVICES	$ 1	54			55
SHARES ISSUED FOR SERVICES, Shares	14
STOCK-BASED COMPENSATION		808			808
STOCK-BASED COMPENSATION, Shares
NET LOSS				(14,355)	(14,355)
OTHER COMPREHENSIVE INCOME
BALANCE at Aug. 31, 2019	$ 208	$ 100,288	$ 0	$ (81,103)	$ 19,393
BALANCE, Shares at Aug. 31, 2019	17,383

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,355)	$ (12,727)	$ (10,480)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	8	6	5
Exchange differences and interest on deposits and held to maturity bonds	(183)	22	124
Stock-based compensation	808	1,547	1,575
Change in fair value of investments	437
Shares issued for services	55	99	72
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(468)	(415)	39
Accounts payable, accrued expenses and payable to related parties	501	(612)	1,257
Deferred revenue	297	(2,449)	1,520
Liability for employee rights upon retirement	2	2	4
Provision for uncertain tax position
Other liabilities	(42)	(130)	53
Total net cash used in operating activities	(12,940)	(14,657)	(5,831)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(15)	(5)	(7)
Purchase of short-term deposits	(24,990)	(7,101)	(3,557)
Purchase of long-term deposits	(4,237)	(15,040)	(17,230)
Purchase of held to maturity securities	(1,357)	(4,429)	(3,869)
Proceeds from maturity of short-term deposits	38,611	17,316	26,551
Proceeds from maturity of held to maturity securities	3,250	2,257	2,417
Funds in respect of employee rights upon retirement	(3)	(2)	(3)
Total net cash provided by (used in) investing activities	11,259	(7,004)	4,302
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants, net of issuance costs		21,657	25
Proceeds from exercise of warrants and options		997	1,561
Total net cash provided by financing activities		22,654	1,586
EFFECT OF EXCHANGE RATE CHANGES ON CASH	14	34	5
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(1,667)	1,027	62
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,996	3,969	3,907
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,329	4,996	3,969
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received	929	826	833
Taxes paid	$ 300		$ 400

Significant Accounting Policies

12 Months Ended

Aug. 31, 2019

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General

Incorporation and operations

Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the "Company", unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the "Subsidiary"), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On July 30, 2019, the Company's subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited. As of August 31, 2019, Oramed HK Limited has no operation.

On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT") and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the "License Agreement"). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People's Republic of China, Macau and Hong Kong (the "Territory"), related to the Company's oral insulin capsule, ORMD-0801 (the "Product"). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary's technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory ("Royalties"), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the "Royalty Term").

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis.

As of August 31, 2019 the Company has received milestone payments in an aggregate amount of $20,500 as follows: the initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the "SPA"). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.

The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company's shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement. Given the Company's continuing involvement through the expected product submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which the Company is entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees are earned.

In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement.

Amounts that were allocated to the License Agreement as of August 31, 2019 aggregated $22,382, all of which were received through the balance sheet date. Through August 31, 2019, the Company recognized revenue in the amount of $10,021, and deferred the remaining amount of $12,361.

The following table sets forth the transactions in deferred revenues balances for the years ended August 31, 2019 and 2018:

	August 31,
	2019			2018

Deferred revenue at the beginning of period	$	13,837		$	16,286
Amounts received		3,000			-
Initial adoption of ASC 606 (note 1k)		(1,773	)		-
Revenue recognized		(2,703	)		(2,449	)
Deferred revenue at the end of period		12,361			13,837
Less – current deferred revenue portion		(2,703	)		(2,449	)
Non-current deferred revenue portion	$	9,658		$	11,388

Development and liquidity risks

The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. To date, we have financed our operations principally through offerings of securities and we will require substantial additional financing at various intervals in order to continue our research and development programs, including significant requirements for operating expenses including intellectual property protection and enforcement, for pursuit of regulatory approvals, and for commercialization of our products. We can provide no assurance that additional funding will be available on a timely basis, on terms acceptable to us, or at all. In the event that we are unable to obtain such financing, we will not be able to fully develop and commercialize our technology. Based on our current cash resources and commitments, we believe we will be able to maintain our current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that we will not need additional funds prior to such time. If there are unexpected increases in our operating expenses, we may need to seek additional financing during the next 12 months.

Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Basis of presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation, expectation of milestone payments and to the expected product submission date for revenue recognition purposes.

Functional currency

The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar ("$" or "dollar"). Therefore, the functional currency of the Company and its Subsidiary is the dollar.

Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Cash equivalents

The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

Fair value measurement:

The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2019, the assets measured at fair value are comprised of equity securities (Level 1). The fair value of held to maturity bonds as presented in note 3 was based on a Level 2 measurement.

As of August 31, 2019, the carrying amounts of cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities of these instruments.

As of August 31, 2019, the carrying amounts of long-term deposits approximate their fair values due to the stated interest rates which approximate market rates.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

There were no Level 3 items for the years ended August 31, 2019, 2018 and 2017.

Marketable securities

1) Available-for-sale securities

In January 2016, the Financial Accounting Standards Board ("FASB") issued guidance which updates certain aspects of recognition, measurement, presentation and disclosure of financial assets and financial liabilities ("ASU 2016-01"). The guidance requires entities to recognize changes in fair value in net income rather than in accumulated other comprehensive income. The Company adopted the provisions of this update in the first quarter of fiscal year 2019. Following the adoption, as of September 1, 2018, the Company classified the available for sale securities (investments in equity securities of D.N.A Biomedical Solutions Ltd. ("D.N.A") and Entera Bio Ltd. ("Entera")) to financial assets measured at fair value through profit or loss. The Company adopted the standard using the modified retrospective method and, accordingly, reclassified the cumulative unrealized gain from accumulated other comprehensive income to a reduction of its accumulated deficit in an amount of $702.

2) Held to maturity securities

All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, management assesses whether there are any indicators that the value of the Company's marketable securities may be impaired, which includes reviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and duration of the decline. In the Company's evaluation, the Company considers its ability and intent to hold these investments for a reasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair value of the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To the extent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimated fair value of the security.

Concentration of credit risks

Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.

As of the date of issuing these financial statements, all amounts due from HTIT with regard to the License Agreement have been received, as described in note 1 above.

As of August 31, 2019, amounts due from HTIT with regard to expense reimbursements owed to the Company totaled $805 and are included in the balance of prepaid expenses and other current assets. HTIT had paid $390 of these reimbursements as of the date of issuing these financial statements.

Income taxes

1. Deferred taxes

Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 10.

Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.

Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.

2. Uncertainty in income tax

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.

Revenue recognition

Under Accounting Standards Codification ("ASC") 605 (which was the authoritative revenue recognition guidance applied for all periods prior to September 1, 2018) given the Company's continuing involvement through the expected product submission in June 2023, amounts received relating to the License Agreement were recognized over the period from which the Company was entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees were earned.

On September 1, 2018, the Company adopted Accounting Standards Update ("ASU") 2014-09 "Revenue from Contracts with Customers (Topic 606)" ("ASC 606"), using the modified retrospective method of adoption. Under this method, the Company applied ASC 606 to the License Agreement at the adoption date and was required to make an adjustment to the September 1, 2018 opening accumulated deficit balance. All prior periods continue to be presented under ASC 605. The most significant impact from adopting ASC 606 was the impact of the timing of recognition of revenue associated with the milestone payment. Under ASC 605, which was the authoritative revenue recognition guidance applied for all periods prior to September 1, 2018, given the Company's continuing involvement through the expected product submission in June 2023, amounts received relating to the License Agreement were recognized over the period from which the Company was entitled to the respective payment and the expected product submission date using a time-based model approach over the periods that the fees were earned. However, under ASC 606, the Company is required to recognize the total transaction price (which includes consideration related to milestones once the criteria for recognition have been satisfied) using the input method over the period the performance obligation is fulfilled. Accordingly, once the consideration associated with a milestone is included in the transaction price, incremental revenue is recognized immediately based on the period of time that has elapsed towards complete satisfaction of the performance obligation. This method results in the recognition of revenue earlier than under ASC 605, and the resulting impact was recorded as a reduction of the opening balance of accumulated deficit at September 1, 2018, as further described below.

Under ASC 606, the Company identified a single performance obligation in the agreement and determined that the license and services are not distinct as the license and services are highly dependent on each other. In other words, HTIT cannot benefit from the license without the related services, and vice versa.

Since the customer benefits from the services as the entity performs, revenue is recognized over time through the expected product submission date in June 2023, using the input method. The Company used the input method to measure the process for the purpose of recognizing revenue, which approximates the straight line attribution. The Company used significant judgment when it determined the product submission date.

Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome.

The Company then evaluates if any of the variable consideration determined in the first step is constrained by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company used significant judgment when it determined the first step of variable consideration.

The potential future royalty consideration is also considered a form of variable consideration under ASC 606 as it is based on a percentage of potential future sales of the Company's products. However, the Company applies the sales-based royalty exception and accordingly will recognize the sales-based royalty amounts when the related sale has occurred. To date, the Company has not recognized any royalty-related revenue.

As of the adoption date, the Company adjusted its accumulated deficit by $1,773 against contract liabilities due to the effect of variable consideration.

Amounts that were allocated to the License Agreement as of August 31, 2019 aggregated $22,383, all of which was received through the balance sheet date. Through August 31, 2019, the Company recognized revenue associated with this agreement in the aggregate amount of $10,022 (of which $2,703 was recognized in the twelve-months period ended August 31, 2019 and $1,773 was recognized as an increase to the September 1, 2018 opening balance of stockholders' equity associated with the impact of the adoption of ASC 606 under the modified retrospective method of adoption), and deferred the remaining amount of $12,361, which is presented as a contract liability on the condensed consolidated balance sheet.

In accordance with ASC 606, the disclosure of the impact of adoption to the Company's consolidated balance sheet as of August 31, 2019 was as follows:

	As reported August 31, 2018		Updated September 1, 2018		Effect of Change

Deferred revenue (short-term)	$	2,449	$	1,230	$	(1,219	)
Deferred revenue (long-term)		11,388		10,834		(554	)
Accumulated deficit		69,223		67,450		(1,773	)

The impact of adoption of ASC 606 on the consolidated balance sheet as of August 31, 2019 and on the consolidated statement of operations for the twelve months ended August 31, 2019 was as follows:

	As reported August 31, 2019		Balances without Adoption of ASC 606		Effect of Change

Revenues	$	2,703	$	2,910	$	(207	)
Cost of revenues		90		90		-
Deferred revenue (short term)		2,703		3,112		(409	)
Deferred revenue (long term)		9,658		10,815		(1,157	)
Accumulated deficit		81,103		82,669		(1,566	)

Cost of revenues

Cost of revenues consists of royalties to the Israel Innovation Authority ("IIA") related to the License Agreement with HTIT. The royalties are recognized when proceeds related to the License Agreement are received.

Research and development

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.

Clinical trial expenses are charged to research and development expense as incurred. The Company accrues for expenses resulting from obligations under contracts with clinical research organizations (CROs). The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company's objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments are recorded as other assets, which will be recognized as expenses as services are rendered.

Stock-based compensation

Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options and restricted stock units ("RSUs") with an exercise price using the Black Scholes pricing model, for stock options with market conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense is not reversed if the market conditions are not satisfied.

When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted to consultants and other non-employees is measured on a final basis at the end of the related service period using the Black Scholes pricing model and is recognized over the related service period using the straight-line method.

On September 1, 2018, the Company adopted ASU 2017-09, "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting" ("ASU 2017-09"), which gives direction on which changes to the terms or conditions of share-based payment awards require an entity to apply modification accounting in ASC Topic 718, see note 7b.

The Company elects to account for forfeitures as they occur.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The weighted average number of stock options, warrants and RSUs excluded from the calculation of diluted net loss was 4,423,325, 1,873,098 and 1,827,719 for the years ended August 31, 2019, 2018 and 2017, respectively.

Newly issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" ("ASU 2016-02"), which supersedes the existing guidance for lease accounting, "Leases (Topic 840)". ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company adopted ASU 2016-02 on September 1, 2019 and expects the impact of this new standard on the consolidated financial statements to be approximately $116 on right of use assets and lease liabilities and does not expect a material impact on its expenses.

In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326)" ("ASU 2016-13"). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

Marketable Securities

12 Months Ended

Aug. 31, 2019

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 3 - MARKETABLE SECURITIES:

Composition:

The Company's marketable securities include investments in equity securities of D.N.A, Entera and in held to maturity bonds.

Composition:

	August 31,
	2019		2018
Short-term:
D.N.A (see b below)	$	557	$	666
Entera (see c below)		304		632
Held to maturity bonds (see d below)		2,840		3,294
	$	3,701	$	4,592
Long-term:
Held to maturity bonds (see d below)	$	1,295	$	2,785
	$	4,996	$	2,785

D.N.A

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

During the years ended August 31, 2019, 2018 and 2017, the Company did not sell any of the D.N.A ordinary shares. As of August 31, 2019, the Company owns approximately 6.9% of D.N.A's outstanding ordinary shares.

The cost of the securities as of August 31, 2019, 2018 and 2017 is $595.

Entera

Entera ordinary shares have been traded on Nasdaq since June 28, 2018. The Company measures the investment at fair value from such date, since it has a readily determinable fair value (prior to such date the investment was accounted for as a cost method investment (amounting to $1)).

Held to maturity bonds

The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2019, are as follows:

	August 31, 2019
	Amortized cost		Gross unrealized gains		Estimated fair value
Short-term:
Commercial bonds	$	2,808	$	6	$	2,814
Accrued interest		32		-		32

Long-term		1,295		4		1,299
	$	4,135	$	10	$	4,145

As of August 31, 2019, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $1,295 and the yield to maturity rates vary between 2.55% to 3.20%.

The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2018, are as follows:

	August 31, 2018
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	3,259	$	(17	)	$	3,242
Accrued interest		35		-			35

Long-term		2,785		(17	)		2,768
	$	6,079	$	(34	)	$	6,045

As of August 31, 2018, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $2,785 and the yield to maturity rates vary between 1.45% to 3.13%.

Held to maturity securities which will mature during the 12 months from the balance sheet date are included in short-term marketable securities. Held to maturity securities with maturity dates of more than one year are considered long-term marketable securities.

Commitments

12 Months Ended

Aug. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS

NOTE 6 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera, to D.N.A, retaining 117,000 ordinary shares after a stock split which was performed by Entera in July 2018. In consideration for the shares sold to D.N.A, the Company received, among other payments, ordinary shares of D.N.A (see also note 3).

As part of this agreement, the Subsidiary entered into a patent transfer agreement (the "Patent Transfer Agreement") according to which the Subsidiary assigned to Entera all of its right, title and interest in and to a certain patent application related to the oral administration of proteins that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. On December 11, 2018, Entera announced that it had entered into a research collaboration and license agreement (the "Amgen License") with Amgen related to research of inflammatory disease and other serious illnesses. As reported by Entera, under the terms of the Amgen License, Entera will receive a modest initial technology access fee from Amgen and will be responsible for preclinical development at Amgen's expense. Entera will be eligible to receive up to $270,000 in aggregate payments, as well as tiered royalties up to mid-single digits, upon achievement of various clinical and commercial milestones if Amgen decides to move all of these programs forward. Amgen is responsible for clinical development, manufacturing and commercialization of any of the resulting programs. To the extent the Amgen License results in net revenues as defined in the Patent Transfer Agreement, the Subsidiary will be entitled to the aforementioned royalties.

In addition, as part of a consulting agreement with a third party, dated February15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011.

On January 3, 2017, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016.

The annual lease payment was New Israeli Shekel ("NIS") 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index ("CPI") (as of August 31, 2019, the future lease payments until the expiration of the lease agreement will be $77, based on the exchange rate as of August 31, 2019).

As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments.

The lease expenses related to the Israeli offices for the years ended August 31, 2019, 2018 and 2017 were $37, $32 and $32, respectively.

On December 18, 2017, the Subsidiary entered into an agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $2,905 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $1,542 of which was recognized in research and development expenses through August 31, 2019.

On February 14, 2018, the Subsidiary entered into a Clinical Research Organization Services Agreement with a third party, effective as of November 1, 2017, to retain it as a clinical research organization ("CRO") for the Subsidiary's three-month dose-ranging clinical trial for its oral insulin capsule for type 2 diabetes patients and, on May 20, 2019, the Subsidiary entered into amendments to such agreement. As consideration for its services, the Subsidiary will pay the CRO a total amount of $10,206 during the term of the engagement and based on achievement of certain milestones, of which $6,408 was recognized in research and development expenses through August 31, 2019.

On May 21, 2018, the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary's food effect clinical trial for its oral insulin capsule. As consideration for its services, the Subsidiary will pay the CRO a total amount of $1,166 during the term of the engagement and based on achievement of certain milestones, $1,141 of which was recognized in research and development expenses through August 31, 2019.

On July 29, 2019, the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary's dose-ranging clinical trial for its oral insulin. As consideration for its services, the Subsidiary will pay the CRO a total amount of $658 during the term of the engagement and based on achievement of certain milestones, of which no cost was recognized through August 31, 2019.

Grants from the Israel Innovation Authority ("IIA")

Under the terms of the Company's funding from the IIA, royalties of 3% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.

Following an amendment to applicable regulations that was published by the IIA, the royalties rate that the Company is obligated to pay to the IIA was reduced from 3.5% to 3%, and the difference in the amount of $86 was recognized as a reduction in cost of revenue in fiscal 2018.

At the time the grants were received, successful development of the related projects was not assured. The total amount that was received through August 31, 2019 was $2,207. As of August 31, 2019, the Company has recorded expenses of $615 and paid $224.

The royalty expenses which are related to the funded project were recognized in cost of revenues in the year ended August 31, 2019 and in prior periods.

For the years ended August 31, 2019, 2018 and 2017, no grants from the IIA were recognized.

Stockholders' Equity

12 Months Ended

Aug. 31, 2019

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 7 - STOCKHOLDERS' EQUITY:

The following are the significant capital stock transactions that took place during the years ended August 31, 2019, 2018 and 2017:

On July 2, 2018, the Company entered into a Securities Purchase Agreement with each of three investors (the "Purchasers"), pursuant to which the Company agreed to sell, in a registered direct offering (the "Offering") an aggregate of 2,892,000 units (the "Units"), each Unit consisting of one share of the Company's common stock, par value $0.012 per share, and a warrant to purchase one share of common stock at an exercise price of $7.25 per share (the "Warrants"), to the Purchasers for an offering price of $6.25 per Unit. The Warrants will be exercisable commencing six months following their issuance for a period of three and one-half years from the date of issuance. For accounting purposes, the warrants were classified as equity considering the warrant conditions. The closing of the sale of the Units occurred on July 6, 2018. The net proceeds to the Company from the Offering, after deducting the placement agent's fees and expenses and the Company's Offering expenses were approximately $16,484.

On July 2, 2018, the Company entered into a letter agreement with H.C. Wainwright & Co., LLC ("HCW"), pursuant to which HCW agreed to serve as exclusive placement agent for the Company in any offering of the Company occurring between July 2, 2018 and August 1, 2018. For its services in the Offering, HCW received a fee equal to 7% of the gross proceeds raised in the Offering and a management fee of 1% of the gross proceeds raised in the Offering, up to $50,000 for non-accountable expenses as well as warrants to purchase up to 115,680 shares of common stock of the Company, exercisable commencing six months following their issuance for a period of three and one-half years from the date of issuance and with an exercise price of $7.8125 per share. The Company recognized the fair value of the warrants as a share based payment which was included as part of the offering costs. Upon the exercise of the Warrants, HCW will receive a fee equal to 7% of the gross proceeds raised as a result of such exercise. The agreement with HCW was terminated on July 19, 2019.

On September 5, 2019, we entered into an Equity Distribution Agreement, or the Sales Agreement, pursuant to which we may, from time to time and at our option, issue and sell shares of our common stock having an aggregate offering price of up to $15,000,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to our effective shelf registration statement on Form S-3 including a prospectus dated February 2, 2017, as supplemented by a prospectus supplement dated September 5, 2019. We will pay the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the Sales Agreement. As of August 31, 2019, no shares were sold under the Sales Agreement.

In August 2019, the Company became aware of a shareholder derivative claim and putative class action alleging, among other things, that the Company's Second Amended and Restated 2008 Stock Incentive Plan (the "2008 Plan") may have terminated in 2018. However, the Company disputes these claims and believes that the 2008 Plan does not terminate until 2026 and any suggestion to the contrary is not well-founded. For the sake of clarity and out of an abundance of caution, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan") at its 2019 shareholders meeting. The 2019 Plan allows the Company to grant up to 1,000,000 options. Since the Company has granted options during the time after the 2008 Plan allegedly terminated, and out of an abundance of caution, the Company canceled these grants and re-granted certain of these options under the 2019 Plan in the same amounts and under the same terms as the original grants. The cancelation and reissuance was approved by the Company's board of directors on September 11, 2019. Out of the available 1,000,000 options under the 2019 Plan, the Company has granted 563,646 to replace the options under dispute as mentioned above. The cancellation of the award accompanied by the concurrent grant of a replacement award was accounted for as modification of the terms of the cancelled award. Since the replacement award was given under the same terms as the cancelled award, no incremental compensation cost was recognized.

As of August 31, 2019, the Company had outstanding warrants exercisable commencing January 6, 2019 for 3,007,680 shares of common stock at exercise prices ranging from $7.25 to $7.8125 per share and expiring on January 6, 2022.

The following table presents the warrant activity for the years ended August 31, 2019, 2018 and 2017:

	Year ended August 31,
	2019				2018					2017
	Warrants		Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price
Warrants outstanding at beginning of year		3,007,680	$	7.27		166,642		$	6.46		615,338		$	5.92
Issued		-	$	-		3,007,680		$	7.27		-		$	-
Exercised		-	$	-		(138,071	)	$	5.73		(248,882	)	$	4.99
Expired		-	$	-		(28,571	)	$	10.00		(199,814	)	$	6.82
Warrants outstanding at end of year		3,007,680	$	7.27		3,007,680		$	7.27		166,642		$	6.46
Warrants exercisable at end of year		3,007,680	$	7.27		-		$	-		166,642		$	6.46

Stock-Based Compensation

12 Months Ended

Aug. 31, 2019

Share-based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

NOTE 8 - STOCK-BASED COMPENSATION:

During the year ended August 31, 2019, the Company made awards under the 2008 Plan. Beginning September 11, 2019, the Company began making awards under the 2019 Plan, under which, the Company has reserved a pool of 1,000,000 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time. Under the 2019 Plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.

The following are the significant stock options transactions with employees, board members and non-employees made during the years ended August 31, 2019, 2018 and 2017:

On February 9, 2017, options to purchase an aggregate of 27,731 shares of the Company were granted to four members of the Company's Board of Directors as follows: (a) 16,337 options at an exercise price of $1 per share (lower than the traded market price of $6.23 on the date of grant). The fair value of these options on the date of grant was $90, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years; (b) 11,394 options at an exercise price of $6.23 per share (equivalent to the traded market price on the date of grant). The fair value of these options on the date of grant was $45, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years. All the options vested immediately and expire on February 9, 2027.

On March 20, 2017, options to purchase an aggregate of 37,152 of the Company's shares of common stock were granted to a consultant at an exercise price of $6.00 per share (higher than the traded market price of $5.96 on the date of grant). The options expire on March 20, 2027. The options vest in 24 consecutive equal monthly installments of 1,548 shares of common stock each, commencing March 31, 2017. The fair value of these options on the date of grant was $177.

On July 30, 2018, the vesting schedule of the options was amended and restated, effective July 1, 2018, as follows: the 12,384 of the options that remain unvested will vest in 24 consecutive equal monthly installments of 516 shares each, commencing July 31, 2018. The amendment did not have any impact on the Company's financial statements.

On June 30, 2017, the Company granted options to purchase shares of the Company and RSUs as follows:

(1)

To the Chief Executive Officer, options to purchase an aggregate of 147,000 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). 49,000 of such options vested on December 31, 2017, as the Company share price reached the target of $8.00 per share, and the remainder will vest in two equal annual installments of 49,000, on each of December 31, 2018 and 2019, subject to the Company share price reaching the target of $9.50 per share and $12.50 per share, respectively. These options expire on June 30, 2027. The fair value of the options at the date of grant was $585 using the Monte Carlo model, which utilizes multiple input variables to estimate the probability that market conditions will be achieved, and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 75.00%; risk-free interest rates of 2.34%; and expected term of 10 years.

(2)

To the Chief Scientific Officer: (a) 75,000 RSUs representing a right to receive shares of the Company's common stock which vested immediately, have an exercise price of $0.012 per share of common stock and expire on June 30, 2027. The total fair value of these RSUs on the date of grant was $582, using the quoted closing market share price of $7.77 on Nasdaq on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2018, none of these RSUs were exercised; and (b) options to purchase an aggregate of 69,999 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). 23,333 of such options vested on December 31, 2017 and the remainder will vest in two equal annual installments of 23,333, on each of December 31, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $359, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years.

(3)

To four members of the Company's Board of Directors, options to purchase an aggregate of 67,092 shares of the Company (16,773 options to each director), at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). 22,364 of such options (5,591 options for each director) vested on December 31, 2017 and the remainder will vest in two equal annual installments, on each of December 31, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $344, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years.

(4)

To a member of the Company's Board of Directors, options to purchase an aggregate of 56,773 shares of the Company at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). 15,591 of such options vested on December 31, 2017 and the remainder will vest in three annual installments, 15,591 of which will vest on each of December 31, 2018 and 2019, and 10,000 of which will vest on December 31, 2020. These options expire on June 30, 2027. The fair value of these options on the date of grant was $294, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.15%; risk-free interest rates of 2.14%; and expected term of 6.18 years.

(5)

To employees of the Subsidiary, options to purchase an aggregate of 38,901 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). 4,912 of such options vested on December 31, 2017, 22,777 of such options were forfeited through August 31, 2018, 1,388 options expired through August 31, 2018 and the remainder will vest in two equal annual installments, on each of December 31, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $200, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years.

On July 19, 2017, options to purchase an aggregate of 20,001 shares of the Company were granted to an employee of the Subsidiary at an exercise price of $8.57 per share (equivalent to the traded market price on the date of grant). 6,667 of such options vested on December 31, 2017 and the remainder will vest in two equal annual installments, on each of December 31, 2018 and 2019. These options expire on July 19, 2027. The fair value of these options on the date of grant was $113, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $8.57; dividend yield of 0% for all years; expected volatility of 74.65%; risk-free interest rates of 1.83%; and expected term of 6 years.

On January 31, 2018, the Company granted options to purchase an aggregate of 159,000 shares of the Company at an exercise price of $8.14 per share (equivalent to the traded market price on the date of grant) as follows: 97,000 to the Chief Executive Officer; 47,000 to the Chief Scientific Officer; and 15,000 to an employee of the Subsidiary. The options will vest in four equal annual installments, on each of January 1, 2019, 2020, 2021 and 2022. These options expire on January 31, 2028. The fair value of all these options on the date of grant was $857, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $8.14; dividend yield of 0% for all years; expected volatility of 71.96%; risk-free interest rates of 2.66%; and expected term of 6.25 years.

On each of April 8, 2018 and May 3, 2018, the Company granted options to purchase 30,000 shares of the Company to an employee of the Subsidiary at exercise prices of $7.05 and $6.70 per share, respectively (equivalent to the traded market price on the date of grant). The options vest in sixteen consecutive equal installments on the last day of each quarter commencing June 30, 2018. 30,000 options expire on April 8, 2028 and 30,000 options expire on May 3, 2028. The fair value of all these options on the date of grant was $269, using the Black Scholes option-pricing model and was based on the following assumptions: (a) for the options granted on April 8, 2018: stock price of $7.05; dividend yield of 0% for all years; expected volatility of 71.54%; risk-free interest rates of 2.70%; and expected term of 6.07 years; and (b) for the options granted on May 3, 2018: stock price of $6.70; dividend yield of 0% for all years; expected volatility of 71.62%; risk-free interest rates of 2.90%; and expected term of 6.02 years.

On February 26, 2019, the Company granted options to purchase an aggregate of 360,000 shares of common stock of the Company at an exercise price of $3.16 per share (equivalent to the closing price of the Company's common stock on the date of grant) as follows: 196,500 to the Chief Executive Officer; 104,000 to the Chief Scientific Officer; and 59,500 to employees of the Subsidiary. The options will vest in four equal annual installments, on each of December 31, 2019, 2020, 2021 and 2022. These options expire on February 26, 2029. The fair value of all these options on the date of grant was $731, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $3.16; dividend yield of 0% for all years; expected volatility of 69.05%; risk-free interest rates of 2.54%; and expected term of 6.25 years. On September 11, 2019, the options were canceled and re-granted at the same terms under the 2019 Plan.

On April 10, 2019 and April 15, 2019, the Company granted options to its directors to purchase an aggregate of 30,000 shares of common stock of the Company at an exercise price of $4.17 and $4.13 per share, respectively (equivalent to the closing price of the Company's common stock on the date of grant). 20,000 of such options vested immediately and the remaining 10,000 options will vest on December 31, 2019. The fair value of all these options on the date of grant was $64, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $4.13 and $4.17, respectively; dividend yield of 0% for all years; expected volatility of 54.64% and 66.40%, respectively; risk-free interest rates of 2.37% and 2.28%, respectively; and expected term of 5 and 5.5 years, respectively. On September 11, 2019, the options were canceled and re-granted at the same terms under the 2019 Plan.

On June 17, 2019, the Company granted options to its Chief Financial Officer to purchase an aggregate of 33,146 shares of common stock of the Company at an exercise price of $3.55 per share (equivalent to the closing price of the Company's common stock on the date of grant). 5,396 of such options will vest on December 31, 2019 and the remaining 27,750 will vest in 3 equal installments on each of December 31, 2020, December 31, 2021 and December 31, 2022. The fair value of all these options on the date of grant was $74, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $3.55; dividend yield of 0% for all years; expected volatility of 67.79%; risk-free interest rates of 2.03%; and expected term of 6.25 years. On September 11, 2019, the options were canceled and re-granted at the same terms under the 2019 Plan.

Options to employees, directors and non-employees

The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model or Monte Carlo model with the following range of assumptions:

	For options granted in the year ended August 31,
	2019	2018	2017
Expected option life (years)	5-6.25	6.02-6.25	5.00-10.00
Expected stock price volatility (%)	54.64-69.05	71.54-71.96	74.15-77.29
Risk free interest rate (%)	2.03-2.54	2.66-2.90	1.83-2.47
Expected dividend yield (%)	0.0	0.0	0.0

A summary of the status of the stock options granted to employees and directors as of August 31, 2019, 2018 and 2017, and changes during the years ended on those dates, is presented below:


	Year ended August 31,
	2019					2018					2017
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
				$					$					$
Options outstanding at beginning of year		1,208,634			7.25		1,208,549			6.94		904,234			6.75
Changes during the year:
Granted		423,146			3.26		219,000			7.79		427,497			7.51
Forfeited		(136,084	)		5.79		(22,777	)		7.77		-			-
Expired		(231,051	)		7.07		(145,388	)		6.49		(59,282	)		10.27
Exercised							(50,750	)		4.08		(63,900	)		5
Options outstanding at end of year		1,264,645			6.11		1,208,634			7.25		1,208,549			6.94
Options exercisable at end of year		709,383					739,650					808,783
Weighted average fair value of options granted during the year	$	2.06				$	5.14				$	4.75

Expenses recognized in respect of stock options granted to employees and directors, for the years ended August 31, 2019, 2018 and 2017 were $791, $1,350 and $451, respectively.

The total intrinsic value of employees' options exercised during the years ended August 31, 2018 and 2017 was $248 and $85, respectively. None of the options were exercised by employees during the year ended August 31, 2019.

The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2019:

Exercise prices	Number outstanding		Weighted Average Remaining Contractual Life		Weighted average exercise price
$			Years		$
1.00 to 5.88		697,233		6.08		3.97
6.23 to 7.88		313,494		7.93		7.71
8.14 to 12.45		253,918		6.87		10.01
		1,264,645		6.70		6.11

As of August 31, 2019, there were $832 of unrecognized compensation costs related to non-vested options previously granted to employees and directors. The unrecognized compensation costs are expected to be recognized over a weighted average period of 1.25 years.

A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2019, 2018 and 2017, and changes during the years ended on those dates, is presented below:

	Year ended August 31,
	2019					2018				2017
	Number of options			Weighted average exercise price		Number of options		Weighted average exercise price		Number of options			Weighted average exercise price
				$				$					$
Options outstanding at beginning of year		55,486			6.71		55,486		6.71		29,668			8.35
Changes during the year:
Granted							-		-		37,152			6.00
Exercised							-		-		-			-
Forfeited							-		-		-			-
Expired		(8,334	)		9.12		-		-		(11,334	)		8.65
Options outstanding at end of year		47,152			9.51		55,486		6.71		55,486			6.71
Options exercisable at end of year		41,992			6.32		44,134		6.90		27,622			7.43

The Company recorded stock-based compensation of $22, $111 and $59 during the years ended August 31, 2019, 2018 and 2017, respectively, related to non-employees' awards.

None of the options were exercised by non-employees during the years ended August 31, 2019 and 2018.

The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2019:

Range of exercise prices	Number outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
$			Years		$
6.00		37,152		7.66		6.00
7.36		10,000		1.23		7.36
		47,152		6.30		6.29

As of August 31, 2019, there were no unrecognized compensation costs related to non-vested non-employee options.

Restricted stock units

The following table summarizes the activities for unvested RSUs granted to employees and directors for the years ended August 31, 2019, 2018 and 2017:

	Year ended August 31,
	2019			2018			2017
	Number of RSUs
Unvested at the beginning of period		165,796			198,276			201,669
Granted		-			-			178,120
Vested and issued		(290	)		(32,480	)		(159,353	)
Forfeited		(870	)		-			(22,160	)
Outstanding at the end of the period		164,636			165,796			198,276
Vested and unissued		164,636			164,636			164,636

The Company recorded compensation income related to RSUs of $5 for the year ended August 31, 2019 and compensation expense of $86 and $1,064 during the years ended August 31, 2018 and 2017, respectively, related to RSU awards.

As of August 31, 2019, there were no unrecognized compensation costs related to RSUs.

Taxes on Income

12 Months Ended

Aug. 31, 2019

Income Tax Disclosure [Abstract]

TAXES ON INCOME

NOTE 10 - TAXES ON INCOME:

Corporate taxation in the U.S.

The applicable corporate tax rate for the Company is 21% following the U.S. Tax Cuts and Jobs Act (the "TCJA"), excluding state tax and local tax. On December 22, 2017, the TCJA was signed into law, which among other changes reduced the federal corporate income tax rate from 35% to 21%, effective January 1, 2018.

As of August 31, 2019, the Company has an accumulated tax loss carryforward of approximately $14,336 (as of August 31, 2018, approximately $12,053). Under U.S. tax laws, subject to certain limitations, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carryforward will expire in the years 2026 through 2038.

Corporate taxation in Israel:

The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2019, 2018 and 2017 are 23%, 23% and 24%, respectively.

As of August 31, 2019, the Subsidiary has an accumulated tax loss carryforward of approximately $44,469 (as of August 31, 2018, approximately $34,695). Under the Israeli tax laws, carryforward tax losses have no expiration date.

Deferred income taxes:

	August 31,
	2019			2018			2017
In respect of:

Net operating loss carryforward	$	13,239		$	10,451		$	9,253
Research and development expenses		2,999			2,431			2,046
Less - valuation allowance		(16,238	)		(12,882	)		(11,299	)
Net deferred tax assets	$	-		$	-		$	-

Deferred taxes are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.

The reduction of the tax rate and TCJA had no impact on the net deferred taxes of the Company.

Loss before taxes on income and income taxes included in the income statements of operations:

	Year ended August 31,
	2019		2018		2017
Loss before taxes on income:
U.S.	$	2,283	$	1,934	$	1,115
Outside U.S.		11,772		10,793		8,965
	$	14,055	$	12,727	$	10,080
Taxes on income (tax benefit):
Current:
U.S.		-		-		-
Outside U.S.		300		-		400
	$	300	$	-	$	400

Taxes on income of $300 in the year ended August 31, 2019 resulted from withholding tax deducted from HTIT milestones payments, which were received during the year ended August 31, 2019, according to the License Agreement. As of August 31, 2019, the Company did not expect to reach taxable income in the 5 years following the balance sheet date, and therefore recognized this amount as taxes on income.

Reconciliation of the statutory tax benefit to effective tax expense

Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense:

	Year ended August 31,
	2019			2018			2017
Loss before income taxes as reported in the consolidated statement of comprehensive loss	$	(14,056	)	$	(12,727	)	$	(10,080	)
Statutory tax benefit		(2,952	)		(2,673	)		(3,528	)
Increase in income taxes resulting from:
Change in the balance of the valuation allowance for deferred tax		3,356			1,583			2,080
Disallowable deductions		86			112			327
Influence of different tax rate applicable to the Subsidiary and changes in tax rates from previous years		(490	)		978			1,121
Withholding tax, see note 10d above		300			-			400
Taxes on income for the reported year	$	300		$	-		$	400

Uncertainty in Income Taxes

ASC Topic 740, "Income Taxes" requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense.

The following table summarizes the activity of the Company unrecognized tax benefits:

	Year ended August 31,
	2019		2018		2017
Balance at Beginning of Year	$	11	$	11		11
Decrease in uncertain tax positions for the current year		-		-		-
Balance at End of Year	$	11	$	11	$	11

The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.

The Company is subject to U.S. Federal income tax examinations for the tax years of 2014 through 2018.

The Subsidiary is subject to Israeli income tax examinations for the tax years of 2013 through 2018.

Valuation Allowance Rollforward

	Year ended August 31,
	Balance at beginning of period		Additions		Balance at end of period
Allowance in respect of carryforward tax losses:
Year ended August 31, 2019		12,882		3,356		16,238
Year ended August 31, 2018	$	11,299	$	1,583	$	12,882
Year ended August 31, 2017		9,219		2,080		11,299

Related Parties - Transactions

12 Months Ended

Aug. 31, 2019

RELATED PARTIES - TRANSACTIONS

NOTE 11 - RELATED PARTIES - TRANSACTIONS:

During each of the fiscal years of 2019, 2018 and 2017, the Company paid to directors $100 as directors' fees.

On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. ("KNRY"), an Israeli company owned by the CSO, whereby the CEO and the CSO, through KNRY, provide services to the Company (the "Consulting Agreements"). The Consulting Agreements are both terminable by either party upon 140 days, prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($36) and NIS 80,454 ($23), respectively.

In addition to the Consulting Agreements, based on a relocation cost analysis prepared by consulting company ORI - Organizational Resources International Ltd., the Company pays for certain direct costs, related taxes and expenses incurred in connection with the relocation of the CEO to New York. During fiscal 2019, such relocation expenses totaled $486.

Balances with related parties:

	August 31,
	2019		2018
Accounts payable and accrued expenses - KNRY	$	46	$	46
Accounts payable and accrued expenses – CEO (relocation)	$	23	$	-

Significant Accounting Policies (Policies)

12 Months Ended

Aug. 31, 2019

Accounting Policies [Abstract]

General

General

Incorporation and operations

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the "Subsidiary"), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On July 30, 2019, the Company's subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited. As of August 31, 2019, Oramed HK Limited has no operation.

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

The following table sets forth the transactions in deferred revenues balances for the years ended August 31, 2019 and 2018:

	August 31,
	2019			2018

Deferred revenue at the beginning of period	$	13,837		$	16,286
Amounts received		3,000			-
Initial adoption of ASC 606 (note 1k)		(1,773	)		-
Revenue recognized		(2,703	)		(2,449	)
Deferred revenue at the end of period		12,361			13,837
Less – current deferred revenue portion		(2,703	)		(2,449	)
Non-current deferred revenue portion	$	9,658		$	11,388

Development and liquidity risks

Basis of presentation

Basis of presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

Use of estimates in the preparation of financial statements

Functional currency

Functional currency

Principles of consolidation

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Cash equivalents

Cash equivalents

Fair value measurement:

Fair value measurement:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2019, the carrying amounts of cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities of these instruments.

As of August 31, 2019, the carrying amounts of long-term deposits approximate their fair values due to the stated interest rates which approximate market rates.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

There were no Level 3 items for the years ended August 31, 2019, 2018 and 2017.

Marketable securities

Marketable securities

1) Available-for-sale securities

2) Held to maturity securities

Concentration of credit risks

Concentration of credit risks

As of the date of issuing these financial statements, all amounts due from HTIT with regard to the License Agreement have been received, as described in note 1 above.

Income taxes

Income taxes

1. Deferred taxes

2. Uncertainty in income tax

Revenue recognition

Revenue recognition

As of the adoption date, the Company adjusted its accumulated deficit by $1,773 against contract liabilities due to the effect of variable consideration.

In accordance with ASC 606, the disclosure of the impact of adoption to the Company's consolidated balance sheet as of August 31, 2019 was as follows:

	As reported August 31, 2018		Updated September 1, 2018		Effect of Change

Deferred revenue (short-term)	$	2,449	$	1,230	$	(1,219	)
Deferred revenue (long-term)		11,388		10,834		(554	)
Accumulated deficit		69,223		67,450		(1,773	)

The impact of adoption of ASC 606 on the consolidated balance sheet as of August 31, 2019 and on the consolidated statement of operations for the twelve months ended August 31, 2019 was as follows:

	As reported August 31, 2019		Balances without Adoption of ASC 606		Effect of Change

Revenues	$	2,703	$	2,910	$	(207	)
Cost of revenues		90		90		-
Deferred revenue (short term)		2,703		3,112		(409	)
Deferred revenue (long term)		9,658		10,815		(1,157	)
Accumulated deficit		81,103		82,669		(1,566	)

Cost of revenues

Cost of revenues

Research and development

Research and development

Stock-based compensation

Stock-based compensation

The Company elects to account for forfeitures as they occur.

Loss per common share

Loss per common share

Newly issued Accounting Pronouncements

Newly issued Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Aug. 31, 2019

Accounting Policies [Abstract]

Schedule of activities for deferred revenues

	August 31,
	2019			2018

Deferred revenue at the beginning of period	$	13,837		$	16,286
Amounts received		3,000			-
Initial adoption of ASC 606 (note 1k)		(1,773	)		-
Revenue recognized		(2,703	)		(2,449	)
Deferred revenue at the end of period		12,361			13,837
Less – current deferred revenue portion		(2,703	)		(2,449	)
Non-current deferred revenue portion	$	9,658		$	11,388

Schedule of impact of adoption of ASC 606

	As reported August 31, 2018		Updated September 1, 2018		Effect of Change

Deferred revenue (short-term)	$	2,449	$	1,230	$	(1,219	)
Deferred revenue (long-term)		11,388		10,834		(554	)
Accumulated deficit		69,223		67,450		(1,773	)

	As reported August 31, 2019		Balances without Adoption of ASC 606		Effect of Change

Revenues	$	2,703	$	2,910	$	(207	)
Cost of revenues		90		90		-
Deferred revenue (short term)		2,703		3,112		(409	)
Deferred revenue (long term)		9,658		10,815		(1,157	)
Accumulated deficit		81,103		82,669		(1,566	)

Long-Term Deposits and Investment (Tables)

12 Months Ended

Aug. 31, 2019

Debt Disclosure [Abstract]

Schedule of long-term deposits

	August 31,
	2019		2018

Bank deposits (see (1) below)	$	-	$	13,541
Lease car deposits		1		1
	$	1	$	13,542

(1)	Represents U.S. dollar bank deposits which carry fixed annual interest rates between 1.80% to 3.44%, with maturities of more than one year from the balance sheet date. The latest maturity date is during the fiscal year ending August 31, 2020.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Stockholders' Equity (Tables)

12 Months Ended

Aug. 31, 2019

Equity [Abstract]

Schedule of warrant activity

	Year ended August 31,
	2019				2018					2017
	Warrants		Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price		Warrants			Weighted-Average Exercise Price
Warrants outstanding at beginning of year		3,007,680	$	7.27		166,642		$	6.46		615,338		$	5.92
Issued		-	$	-		3,007,680		$	7.27		-		$	-
Exercised		-	$	-		(138,071	)	$	5.73		(248,882	)	$	4.99
Expired		-	$	-		(28,571	)	$	10.00		(199,814	)	$	6.82
Warrants outstanding at end of year		3,007,680	$	7.27		3,007,680		$	7.27		166,642		$	6.46
Warrants exercisable at end of year		3,007,680	$	7.27		-		$	-		166,642		$	6.46

Stock-Based Compensation (Tables)

12 Months Ended

Aug. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of fair value of option grant using the Black Scholes option-pricing model

	For options granted in the year ended August 31,
	2019	2018	2017
Expected option life (years)	5-6.25	6.02-6.25	5.00-10.00
Expected stock price volatility (%)	54.64-69.05	71.54-71.96	74.15-77.29
Risk free interest rate (%)	2.03-2.54	2.66-2.90	1.83-2.47
Expected dividend yield (%)	0.0	0.0	0.0

Schedule of stock options granted to employees and directors


	Year ended August 31,
	2019					2018					2017
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
				$					$					$
Options outstanding at beginning of year		1,208,634			7.25		1,208,549			6.94		904,234			6.75
Changes during the year:
Granted		423,146			3.26		219,000			7.79		427,497			7.51
Forfeited		(136,084	)		5.79		(22,777	)		7.77		-			-
Expired		(231,051	)		7.07		(145,388	)		6.49		(59,282	)		10.27
Exercised							(50,750	)		4.08		(63,900	)		5
Options outstanding at end of year		1,264,645			6.11		1,208,634			7.25		1,208,549			6.94
Options exercisable at end of year		709,383					739,650					808,783
Weighted average fair value of options granted during the year	$	2.06				$	5.14				$	4.75

Schedule of options granted to employees and directors outstanding and exercisable

Exercise prices	Number outstanding		Weighted Average Remaining Contractual Life		Weighted average exercise price
$			Years		$
1.00 to 5.88		697,233		6.08		3.97
6.23 to 7.88		313,494		7.93		7.71
8.14 to 12.45		253,918		6.87		10.01
		1,264,645		6.70		6.11

Schedule of stock options granted to non-employees outstanding

	Year ended August 31,
	2019					2018				2017
	Number of options			Weighted average exercise price		Number of options		Weighted average exercise price		Number of options			Weighted average exercise price
				$				$					$
Options outstanding at beginning of year		55,486			6.71		55,486		6.71		29,668			8.35
Changes during the year:
Granted							-		-		37,152			6.00
Exercised							-		-		-			-
Forfeited							-		-		-			-
Expired		(8,334	)		9.12		-		-		(11,334	)		8.65
Options outstanding at end of year		47,152			9.51		55,486		6.71		55,486			6.71
Options exercisable at end of year		41,992			6.32		44,134		6.90		27,622			7.43

Schedule of concerning the options granted to non-employees outstanding and exercisable

Range of exercise prices	Number outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
$			Years		$
6.00		37,152		7.66		6.00
7.36		10,000		1.23		7.36
		47,152		6.30		6.29

Schedule of activities for unvested RSUs granted to employees and directors

	Year ended August 31,
	2019			2018			2017
	Number of RSUs
Unvested at the beginning of period		165,796			198,276			201,669
Granted		-			-			178,120
Vested and issued		(290	)		(32,480	)		(159,353	)
Forfeited		(870	)		-			(22,160	)
Outstanding at the end of the period		164,636			165,796			198,276
Vested and unissued		164,636			164,636			164,636

Taxes on Income (Tables)

12 Months Ended

Aug. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of deferred income taxes

	August 31,
	2019			2018			2017
In respect of:

Net operating loss carryforward	$	13,239		$	10,451		$	9,253
Research and development expenses		2,999			2,431			2,046
Less - valuation allowance		(16,238	)		(12,882	)		(11,299	)
Net deferred tax assets	$	-		$	-		$	-

Schedule of income taxes included in the income statements

	Year ended August 31,
	2019		2018		2017
Loss before taxes on income:
U.S.	$	2,283	$	1,934	$	1,115
Outside U.S.		11,772		10,793		8,965
	$	14,055	$	12,727	$	10,080
Taxes on income (tax benefit):
Current:
U.S.		-		-		-
Outside U.S.		300		-		400
	$	300	$	-	$	400

Schedule of reconciliation of income taxes

	Year ended August 31,
	2019			2018			2017
Loss before income taxes as reported in the consolidated statement of comprehensive loss	$	(14,056	)	$	(12,727	)	$	(10,080	)
Statutory tax benefit		(2,952	)		(2,673	)		(3,528	)
Increase in income taxes resulting from:
Change in the balance of the valuation allowance for deferred tax		3,356			1,583			2,080
Disallowable deductions		86			112			327
Influence of different tax rate applicable to the Subsidiary and changes in tax rates from previous years		(490	)		978			1,121
Withholding tax, see note 10d above		300			-			400
Taxes on income for the reported year	$	300		$	-		$	400

Schedule of unrecognized tax benefits activity

	Year ended August 31,
	2019		2018		2017
Balance at Beginning of Year	$	11	$	11		11
Decrease in uncertain tax positions for the current year		-		-		-
Balance at End of Year	$	11	$	11	$	11

Schedule of valuation allowance rollforward

	Year ended August 31,
	Balance at beginning of period		Additions		Balance at end of period
Allowance in respect of carryforward tax losses:
Year ended August 31, 2019		12,882		3,356		16,238
Year ended August 31, 2018	$	11,299	$	1,583	$	12,882
Year ended August 31, 2017		9,219		2,080		11,299

Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Accounting Policies [Abstract]
Deferred revenue at the beginning of period	$ 13,837	$ 16,286
Amounts received	3,000
Initial adoption of ASC 606 (note 1k)	(1,773)
Revenue recognized	(2,703)	(2,449)
Deferred revenue at the end of period	12,361	13,837
Less - current deferred revenue portion	2,703	2,449
Non-current deferred revenue portion	$ 9,658	$ 11,388

Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
New Accounting Pronouncement, Early Adoption [Line Items]
Revenues	$ 2,703	$ 2,449	$ 2,456
Cost of revenues	90	(86)	$ 187
Deferred revenue (short-term)	2,703	2,449
Deferred revenue (long-term)	9,658	11,388
Accumulated deficit	81,103	69,223
Updated September 1, 2018 [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Deferred revenue (short-term)		1,230
Deferred revenue (long-term)		10,834
Accumulated deficit		67,450
Effect of Change [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Revenues	(207)
Cost of revenues
Deferred revenue (short-term)	(409)	(1,219)
Deferred revenue (long-term)	(1,157)	(554)
Accumulated deficit	(1,566)	$ (1,773)
Balances without Adoption of ASC 606 [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Revenues	2,910
Cost of revenues	90
Deferred revenue (short-term)	3,112
Deferred revenue (long-term)	11,599
Accumulated deficit	$ 82,669

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 28, 2015	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017	Jul. 31, 2015
Significant Accounting Policies (Textual)
Milestone payment received			$ 20,500
Prepaid expenses and other current assets			$ 1,042	$ 574
Uncertain tax percentage, description			The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
Right of use assets and lease liabilities			$ 116
License agreement value			22,383
Recognize revenue			10,022
Deferred costs			$ 12,361
Recognized revenue, description			Of which $2,703 was recognized in the twelve-months period ended August 31, 2019 and $1,773 was recognized as an increase to the September 1, 2018 opening balance of stockholders’ equity associated with the impact of the adoption of ASC 606 under the modified retrospective method of adoption
Securities excluded from the calculation of diluted net loss			4,423,325	1,873,098	1,827,719
Non-refundable amount						$ 500
Milestone payment, description			The initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019.
Reduction of accumulated deficit			$ 702
Accumulated deficit			(81,103)	$ (69,223)
Adjusted accumulated deficit against contract liabilities			1,773
License Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value		$ 38,883
License agreement value			22,382
Recognize revenue			10,021
Deferred costs			$ 12,361
Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value		10,617
Total consideration		49,500
Issuance expenses		$ 23
HTIT [Member]
Significant Accounting Policies (Textual)
Percentages of royalties on net sales			10.00%
Aggregate license costs			$ 37,500
License costs payable			3,000
Amount paid subject to the Company entering into certain agreements			8,000
Payable upon achievement of certain milestones and conditions			26,500
Prepaid expenses and other current assets			805
Issuance expenses			$ 390
Royalty commitment description			In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
Royalty term			15 years
HTIT [Member] \| Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued	1,155,367
Number of common stock issued ,value	$ 12,000

Short-term Deposits (Details) - Dollar Deposits [Member] - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Short-term Deposits	$ 25,252	$ 20,875
Minimum [Member]
Annual interest rate	1.80%	2.06%
Maximum [Member]
Annual interest rate	3.44%	3.01%

Marketable Securities (Details) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018
Short-term:
D.N.A (see b below)	$ 557	$ 666
Entera (see c below)	304	632
Held to maturity bonds (see d below)	2,840	3,294
Marketable securities	3,701	4,592
Long-term:
Held to maturity bonds (see d below)	1,295	2,785
Total marketable securities, noncurrent	$ 4,996	$ 2,785

Marketable Securities (Details 1) - USD ($) $ in Thousands	12 Months Ended
Marketable Securities (Details 1) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018
Summary of held to maturity securities [Abstract]
Amortized cost	$ 4,135	$ 6,079
Gross unrealized gains/losses	10	(34)
Estimated fair value	4,145	6,045
Short-term [Member] \| Accrued interest [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	32	35
Gross unrealized gains/losses
Estimated fair value	32	35
Long-term [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	1,295	2,785
Gross unrealized gains/losses	4	(17)
Estimated fair value	1,299	2,768
Commercial bonds [Member] \| Short-term [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	2,808	3,259
Gross unrealized gains/losses	6	(17)
Estimated fair value	$ 2,814	$ 3,242

Marketable Securities (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Marketable Securities (Textual)
Percentage of ownership interest	6.90%
Cost of securities	$ 595	$ 595	$ 595
Marketable securities	$ 1,295	$ 2,785
Marketable securities maturity dates, description	After one year through two years.	After one year through two years.
Cost method investment	$ 1
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates	2.55%	1.45%
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates	3.20%	3.13%

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 1,337	$ 1,135
Payroll and related accruals	25	80
Institutions	33	29
Other accrued liabilities	1,146	814
Total accounts payable and accrued expenses	$ 2,541	$ 2,058

Commitments (Details) - USD ($) $ in Thousands		1 Months Ended					12 Months Ended
Commitments (Details) - USD ($) $ in Thousands	Dec. 11, 2018	Jul. 29, 2019	May 21, 2018	Feb. 14, 2018	Dec. 18, 2017	Mar. 31, 2011	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017	Oct. 01, 2016	Feb. 15, 2011
Commitments (Textual)
Lease expenses							$ 37	$ 32	$ 32
Total received							2,207
Aggregate payments receive	$ 270,000
Projects recorded expenses							615
Projects paid amount							224
Clinical Research Organization Services Agreement [Member]
Commitments (Textual)
Commitments for consulting services				$ 10,206
Expense which was recognized							6,408
Vendor One [Member]
Commitments (Textual)
Commitments for consulting services					$ 2,905
Expense which was recognized							1,542
Israel Innovation Authority One [Member]
Commitments (Textual)
Total received							$ 86
Israel Innovation Authority One [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage							3.00%
Israel Innovation Authority One [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage							3.50%
Israel Innovation Authority [Member]
Commitments (Textual)
Royalty percentage							3.00%				8.00%
Israel Innovation Authority [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage							100.00%
Israel Innovation Authority [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage							150.00%
Office facilities [Member]
Commitments (Textual)
Operating lease, term										60 months
Lessee, description							The annual lease payment was New Israeli Shekel (“NIS”) 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index (“CPI”) (as of August 31, 2019, the future lease payments until the expiration of the lease agreement will be $77, based on the exchange rate as of August 31, 2019).
Third party [Member] \| Clinical Research Organization Services Agreement [Member]
Commitments (Textual)
Commitments for consulting services		$ 658	$ 1,166
Expense which was recognized							$ 1,141
Entera Bio Ltd. [Member] \| D.N.A [Member]
Commitments (Textual)
Ownership percentage retained						3.00%					8.00%
Ordinary shares after stock split						117,000

Stockholders' Equity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Warrants
Warrants outstanding at beginning of year	3,007,680	166,642	615,338
Issued		3,007,680
Exercised		(138,071)	(248,882)
Expired		(28,571)	(199,814)
Warrants outstanding at end of year	3,007,680	3,007,680	166,642
Warrants exercisable	3,007,680		166,642
Weighted-Average Exercise Price
Weighted-Average Exercise Price, Warrants outstanding	$ 7.27	$ 6.46	$ 5.92
Issued		7.27
Exercised		5.73	4.99
Expired		10.00	6.82
Weighted-Average Exercise Price, Warrants outstanding	7.27	7.27	6.46
Weighted-Average Exercise Price, Warrants exercisable	$ 7.27		$ 6.46

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Sep. 05, 2019	Jul. 02, 2018	Aug. 31, 2019	Aug. 31, 2018
Stockholders' Equity (Textual)
Common stock, par value			$ 0.012	$ 0.012
Stock incentive plan, description			The Company became aware of a shareholder derivative claim and putative class action alleging, among other things, that the Company's Second Amended and Restated 2008 Stock Incentive Plan (the "2008 Plan") may have terminated in 2018. However, the Company disputes these claims and believes that the 2008 Plan does not terminate until 2026 and any suggestion to the contrary is not well-founded. For the sake of clarity and out of an abundance of caution, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan") at its 2019 shareholders meeting. The 2019 Plan allows the Company to grant up to 1,000,000 options. Since the Company has granted options during the time after the 2008 Plan allegedly terminated, and out of an abundance of caution, the Company canceled these grants and re-granted certain of these options under the 2019 Plan in the same amounts and under the same terms as the original grants. The cancelation and reissuance was approved by the Company's board of directors on September 11, 2019. Out of the available 1,000,000 options under the 2019 Plan, the Company has granted 563,646 to replace the options under dispute as mentioned above. The cancellation of the award accompanied by the concurrent grant of a replacement award was accounted for as modification of the terms of the cancelled award. Since the replacement award was given under the same terms as the cancelled award, no incremental compensation cost was recognized.
H.C. Wainwright & Co., LLC [Member]
Stockholders' Equity (Textual)
Outstanding warrants exercisable			3,007,680
Exercise price lower range			$ 7.25
Exercise price upper range			$ 7.8125
Warrants expiration date			Jan. 06, 2022
Sales Agreement [Member]
Stockholders' Equity (Textual)
Common stock aggregate offering price	$ 15,000,000
Percentage of commission	3.00%
Securities Purchase Agreement [Member]
Stockholders' Equity (Textual)
Issuance of common stock, shares		2,892,000
Common stock, par value		$ 0.012
Warrants exercise price		7.25
Offering price		$ 6.25
Net proceeds from offering		$ 16,484
Letter agreement, description		The Company entered into a letter agreement with H.C. Wainwright & Co., LLC ("HCW"), pursuant to which HCW agreed to serve as exclusive placement agent for the Company in any offering of the Company occurring between July 2, 2018 and August 1, 2018. For its services in the Offering, HCW received a fee equal to 7% of the gross proceeds raised in the Offering and a management fee of 1% of the gross proceeds raised in the Offering, up to $50,000 for non-accountable expenses as well as warrants to purchase up to 115,680 shares of common stock of the Company, exercisable commencing six months following their issuance for a period of three and one-half years from the date of issuance and with an exercise price of $7.8125 per share. The Company recognized the fair value of the warrants as a share based payment which was included as part of the offering costs. Upon the exercise of the Warrants, HCW will receive a fee equal to 7% of the gross proceeds raised as a result of such exercise.

Stock-Based Compensation (Details) - Options Held [Member]	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected stock price volatility, minimum (%)	5464.00%	7154.00%	7415.00%
Expected stock price volatility, maximum (%)	6905.00%	7196.00%	7729.00%
Risk free interest rate, minimum (%)	203.00%	266.00%	183.00%
Risk free interest rate, maximum (%)	254.00%	290.00%	247.00%
Expected dividend yield (%)	0.00%	0.00%	0.00%
Minimum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)	5 years	6 years 7 days	5 years
Maximum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)	6 years 2 months 30 days	6 years 2 months 30 days	10 years

Stock-Based Compensation (Details 1) - Employees And Directors [Member] - $ / shares	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Number of options
Options outstanding at beginning of year	1,208,634	1,208,549	904,234
Changes during the year:
Granted	423,146	219,000	427,497
Forfeited	(136,084)	(22,777)
Expired	(231,051)	(145,388)	(59,282)
Exercised		(50,750)	(63,900)
Options outstanding at end of year	1,264,645	1,208,634	1,208,549
Options exercisable at end of year	709,383	739,650	808,783
Weighted average fair value of options granted during the year	$ 2.06	$ 5.14	$ 4.75
Weighted average exercise price
Options outstanding at beginning of year	7.25	6.94	6.75
Changes during the year:
Granted	3.26	7.79	7.51
Forfeited	5.79	7.77
Expired	7.07	6.49	10.27
Exercised		4.08	5
Options outstanding at end of year	$ 6.11	$ 7.25	$ 6.94

Stock-Based Compensation (Details 2) - Employees And Directors [Member]	12 Months Ended
	Aug. 31, 2019 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	1,287,145
Weighted Average Remaining Contractual Life	6 years 8 months 12 days
Weighted average exercise price \| $ / shares	$ 6.11
1.00 to 5.88 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	697,233
Weighted Average Remaining Contractual Life	6 years 29 days
Weighted average exercise price \| $ / shares	$ 3.97
6.23 to 7.88 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	313,494
Weighted Average Remaining Contractual Life	7 years 11 months 4 days
Weighted average exercise price \| $ / shares	$ 7.71
8.14 to 12.45 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	253,918
Weighted Average Remaining Contractual Life	6 years 10 months 14 days
Weighted average exercise price \| $ / shares	$ 10.01

Stock-Based Compensation (Details 3) - Non Employees [Member] - $ / shares	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Number of options
Options outstanding at beginning of year	55,486	55,486	29,668
Changes during the year:
Granted			37,152
Forfeited
Expired	(8,334)		(11,334)
Exercised
Options outstanding at end of year	47,152	55,486	55,486
Options exercisable at end of year	41,992	44,134	27,622
Weighted average fair value of options granted during the year	$ 6.32	$ 6.9	$ 7.43
Weighted average exercise price
Options outstanding at beginning of year	6.71	6.71	8.35
Changes during the year:
Granted			6.00
Forfeited
Expired	9.12		8.65
Exercised
Options outstanding at end of year	$ 9.51	$ 6.71	$ 6.71

Stock-Based Compensation (Details 4) - Non Employees [Member]	12 Months Ended
	Aug. 31, 2019 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	47,152
Weighted Average Remaining Contractual Life	6 years 3 months 19 days
Weighted average exercise price \| $ / shares	$ 6.29
6.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	37,152
Weighted Average Remaining Contractual Life	7 years 7 months 28 days
Weighted average exercise price \| $ / shares	$ 6.00
7.36 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	10,000
Weighted Average Remaining Contractual Life	1 year 2 months 23 days
Weighted average exercise price \| $ / shares	$ 7.36

Stock-Based Compensation (Details 5) - Restricted Stock Units (RSUs) [Member] - Employees And Directors [Member] - shares	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at the beginning of period	165,796	198,276	201,669
Granted			178,120
Vested and issued	(290)	(32,480)	(159,353)
Forfeited	(870)		(22,160)
Outstanding at the end of the period	164,636	165,796	198,276
Vested and unissued	164,636	164,636	164,636

Stock-Based Compensation (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended									12 Months Ended
	Apr. 10, 2019 USD ($) $ / shares shares	May 03, 2018	Apr. 08, 2018	Feb. 09, 2017 USD ($) $ / shares shares	Jun. 17, 2019 USD ($) Installments $ / shares shares	Apr. 15, 2019 USD ($) $ / shares shares	Feb. 26, 2019 USD ($) Installments $ / shares shares	Jul. 30, 2018	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 $ / shares shares	Jul. 19, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) Installments $ / shares shares	Mar. 20, 2017 USD ($) Installments $ / shares shares	Aug. 31, 2019 USD ($) $ / shares shares	Aug. 31, 2018 USD ($) $ / shares shares	Aug. 31, 2017 USD ($) $ / shares shares	Aug. 31, 2015 shares	Aug. 31, 2016 USD ($)
Stock-Based Compensation (Textual)
Stock based compensation \| $														$ 808	$ 1,547	$ 1,575
Intrinsic value of options exercised \| $															$ 248	85
Options vested expiration description														The Company became aware of a shareholder derivative claim and putative class action alleging, among other things, that the Company's Second Amended and Restated 2008 Stock Incentive Plan (the "2008 Plan") may have terminated in 2018. However, the Company disputes these claims and believes that the 2008 Plan does not terminate until 2026 and any suggestion to the contrary is not well-founded. For the sake of clarity and out of an abundance of caution, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan") at its 2019 shareholders meeting. The 2019 Plan allows the Company to grant up to 1,000,000 options. Since the Company has granted options during the time after the 2008 Plan allegedly terminated, and out of an abundance of caution, the Company canceled these grants and re-granted certain of these options under the 2019 Plan in the same amounts and under the same terms as the original grants. The cancelation and reissuance was approved by the Company's board of directors on September 11, 2019. Out of the available 1,000,000 options under the 2019 Plan, the Company has granted 563,646 to replace the options under dispute as mentioned above. The cancellation of the award accompanied by the concurrent grant of a replacement award was accounted for as modification of the terms of the cancelled award. Since the replacement award was given under the same terms as the cancelled award, no incremental compensation cost was recognized.
Weighted average period term														1 year 2 months 30 days
Chief Executive Officer [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments												3
Options vested												49,000
Quoted closing market share price \| $ / shares										$ 8.00
Options granted							196,500		97,000			147,000
Exercise price \| $ / shares												$ 7.77
Fair value of options granted \| $												$ 585
Expiration date												Jun. 30, 2027
Expected dividend yield												0.00%
Expected volatility												75.00%
Risk-free interest rate												2.34%
Expected term												10 years
Chief Executive Officer [Member] \| December 31, 2018 [Member]
Stock-Based Compensation (Textual)
Quoted closing market share price \| $ / shares												$ 9.50
Number of options to vest each installment												49,000
Chief Executive Officer [Member] \| December 31, 2019 [Member]
Stock-Based Compensation (Textual)
Quoted closing market share price \| $ / shares												$ 12.50
Number of options to vest each installment												49,000
Chief Executive Officer [Member] \| December Thirty One Two Thousand Seventeen [Member]
Stock-Based Compensation (Textual)
Quoted closing market share price \| $ / shares												$ 8.00
Director [Member]
Stock-Based Compensation (Textual)
Options vested	20,000					20,000				5,591		16,773
Options granted	30,000					30,000						56,773
Exercise price \| $ / shares	$ 4.17					$ 0.13						$ 7.77
Number of vesting installments \| Installments												3
Fair value of options granted \| $	$ 64					$ 64						$ 294
Expiration date												Jun. 30, 2027
Stock price \| $ / shares	$ 4.13					$ 4.17						$ 7.77
Expected dividend yield	0.00%					0.00%						0.00%
Expected volatility	54.64%					66.40%						74.15%
Risk-free interest rate	2.37%					2.28%						2.14%
Expected term	5 years					5 years 6 months						6 years 2 months 5 days
Unrecognized compensation expense \| $
Director [Member] \| December 31, 2018 [Member]
Stock-Based Compensation (Textual)
Number of options to vest each installment												15,591
Director [Member] \| December 31, 2019 [Member]
Stock-Based Compensation (Textual)
Options vested	10,000					10,000
Number of options to vest each installment												15,591
Director [Member] \| December Thirty One Two Thousand Twenty [Member]
Stock-Based Compensation (Textual)
Number of options to vest each installment												10,000
Director Four [Member]
Stock-Based Compensation (Textual)
Options granted				27,731
Exercise price \| $ / shares				$ 6.23
Fair value of options granted \| $				$ 45
Expiration date				Feb. 09, 2027
Expected dividend yield				0.00%
Expected volatility				77.29%
Risk-free interest rate				1.88%
Expected term				5 years
Options vested expiration description				(a) 16,337 options at an exercise price of $1 per share (lower than the traded market price of $6.23 on the date of grant). The fair value of these options on the date of grant was $90, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years; (b) 11,394 options at an exercise price of $6.23 per share (equivalent to the traded market price on the date of grant).
Consultants [Member]
Stock-Based Compensation (Textual)
Quoted closing market share price \| $ / shares													$ 5.96
Options granted													37,152
Exercise price \| $ / shares													$ 6.00
Number of vesting installments \| Installments													24
Expiration date													Mar. 20, 2027
Vesting, description								The vesting schedule of the options was amended and restated, effective July 1, 2018, as follows: the 12,384 of the options that remain unvested will vest in 24 consecutive equal monthly installments of 516 shares each, commencing July 31, 2018.
Consultants [Member] \| Share-based Compensation Award, Tranche One [Member]
Stock-Based Compensation (Textual)
Options granted													1,548
Fair value of options granted \| $													$ 177
Chief Scientific Officer [Member]
Stock-Based Compensation (Textual)
Options vested										23,333
Options granted							104,000		47,000
Exercise price \| $ / shares												$ 7.77
Fair value of options granted \| $												$ 359
Expiration date												Jun. 30, 2027
Stock price \| $ / shares										$ 7.77
Expected dividend yield												0.00%
Expected volatility												74.77%
Risk-free interest rate												1.89%
Expected term												6 years
Options vested expiration description												(a) 75,000 RSUs representing a right to receive shares of the Company’s common stock which vested immediately, have an exercise price of $0.012 per share of common stock and expire on June 30, 2027. The total fair value of these RSUs on the date of grant was $582, using the quoted closing market share price of $7.77 on Nasdaq on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2018, none of these RSUs were exercised; and (b) options to purchase an aggregate of 69,999 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant).
Chief Scientific Officer [Member] \| December 31, 2018 [Member]
Stock-Based Compensation (Textual)
Number of options to vest each installment												23,333
Chief Scientific Officer [Member] \| December 31, 2019 [Member]
Stock-Based Compensation (Textual)
Number of options to vest each installment												23,333
Subsidiary Employees Three [Member]
Stock-Based Compensation (Textual)
Options vested									15,000	4,912
Quoted closing market share price \| $ / shares									$ 8.14
Options granted									159,000		20,001	38,901
Exercise price \| $ / shares									$ 8.14		$ 8.57	$ 7.77
Fair value of options granted \| $									$ 857		$ 113	$ 200
Expiration date									Jan. 31, 2028		Jul. 19, 2027	Jun. 30, 2027
Stock price \| $ / shares											$ 8.57	$ 7.77
Expected dividend yield									0.00%		0.00%	0.00%
Expected volatility									71.96%		74.65%	74.77%
Risk-free interest rate									2.66%		1.83%	1.89%
Expected term									6 years 2 months 30 days		6 years	6 years
Vesting, description		The Company granted options to purchase 30,000 shares of the Company to an employee of the Subsidiary at exercise prices of $7.05 and $6.70 per share, respectively (equivalent to the traded market price on the date of grant). The options vest in sixteen consecutive equal installments on the last day of each quarter commencing June 30, 2018. 30,000 options expire on April 8, 2028 and 30,000 options expire on May 3, 2028. The fair value of all these options on the date of grant was $269, using the Black Scholes option-pricing model and was based on the following assumptions: (a) for the options granted on April 8, 2018: stock price of $7.05; dividend yield of 0% for all years; expected volatility of 71.54%; risk-free interest rates of 2.70%; and expected term of 6.07 years; and (b) for the options granted on May 3, 2018: stock price of $6.70; dividend yield of 0% for all years; expected volatility of 71.62%; risk-free interest rates of 2.90%; and expected term of 6.02 years.	The Company granted options to purchase 30,000 shares of the Company to an employee of the Subsidiary at exercise prices of $7.05 and $6.70 per share, respectively (equivalent to the traded market price on the date of grant). The options vest in sixteen consecutive equal installments on the last day of each quarter commencing June 30, 2018. 30,000 options expire on April 8, 2028 and 30,000 options expire on May 3, 2028. The fair value of all these options on the date of grant was $269, using the Black Scholes option-pricing model and was based on the following assumptions: (a) for the options granted on April 8, 2018: stock price of $7.05; dividend yield of 0% for all years; expected volatility of 71.54%; risk-free interest rates of 2.70%; and expected term of 6.07 years; and (b) for the options granted on May 3, 2018: stock price of $6.70; dividend yield of 0% for all years; expected volatility of 71.62%; risk-free interest rates of 2.90%; and expected term of 6.02 years.
Options forfeited															22,777
Options expired															1,388
Subsidiary Employees Three [Member] \| Options Held [Member]
Stock-Based Compensation (Textual)
Options vested										6,667
Subsidiary Employees Four [Member]
Stock-Based Compensation (Textual)
Options vested							59,500
Quoted closing market share price \| $ / shares							$ 3.16
Options granted							360,000
Exercise price \| $ / shares							$ 3.16
Number of vesting installments \| Installments							4
Fair value of options granted \| $							$ 731
Expiration date							Feb. 26, 2029
Expected dividend yield							0.00%
Expected volatility							69.05%
Risk-free interest rate							2.54%
Expected term							6 years 2 months 30 days
Chief Financial Officer [Member]
Stock-Based Compensation (Textual)
Options vested					5,396
Options granted					33,146
Exercise price \| $ / shares					$ 3.55
Number of vesting installments \| Installments					3
Fair value of options granted \| $					$ 74
Stock price \| $ / shares					$ 3.55
Expected dividend yield					0.00%
Expected volatility					67.79%
Risk-free interest rate					2.03%
Expected term					6 years 2 months 30 days
Vesting, description					5,396 of such options vested will vest on December 31, 2019 and the remaining 27,750 will vest in 3 equal installments on each of December 31, 2020, December 31, 2021 and December 31, 2022.
2008 Plan [Member]
Stock-Based Compensation (Textual)
Number of shares reserved for grant														1,000,000
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Textual)
Stock based compensation \| $														$ 5	$ 86	$ 1,064
Unrecognized compensation expense \| $														$ 1
Restricted Stock Units (RSUs) [Member] \| Director Four [Member]
Stock-Based Compensation (Textual)
Number of installments \| Installments												2
Options granted										22,364		67,092
Exercise price \| $ / shares												$ 7.77
Fair value of options granted \| $												$ 344
Expiration date												Jun. 30, 2027
Expected dividend yield												0.00%
Expected volatility												74.77%
Risk-free interest rate												1.89%
Expected term												6 years
Employees And Directors [Member]
Stock-Based Compensation (Textual)
Maximum term of the options														10 years
Options granted														423,146	219,000	427,497
Exercise price \| $ / shares														$ 3.26	$ 7.79	$ 7.51
Stock based compensation \| $														$ 791	$ 1,350	$ 451
Intrinsic value of options exercised \| $
Unrecognized compensation expense \| $														$ 832
RSU forfeited
Non Employees [Member]
Stock-Based Compensation (Textual)
Options granted																37,152
Exercise price \| $ / shares																$ 6.00
Stock based compensation \| $														$ 22	$ 111	$ 59
Non Employees [Member] \| Director [Member]
Stock-Based Compensation (Textual)
Unrecognized compensation expense \| $

Financial Income and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Financial income
Income from interest on deposits	$ 909	$ 741	$ 657
Exchange rate differences			7
Income from interest on corporate bonds	152	162	128
Financial income	$ 1,061	$ 903	$ 792

Financial Income and Expenses (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Financial expenses
Exchange rate differences	$ 14	$ 30	$ 17
Bank commissions	4	6	6
Loss from securities	436
Other	31	67	78
Financial expenses	$ 485	$ 103	$ 101

Taxes on Income (Details) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Schedule of deferred income taxes
Net operating loss carryforward	$ 13,239	$ 10,451	$ 9,253
Research and development expenses	2,999	2,431	2,046
Less - valuation allowance	(16,238)	(12,882)	(11,299)
Net deferred tax assets

Taxes on Income (Details 1) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details 1) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Loss before taxes on income:
U.S.	$ 2,283	$ 1,934	$ 1,115
Outside U.S.	11,772	10,793	8,965
Loss before taxes on income	14,055	(12,727)	(10,080)
Current:
U.S.
Outside U.S.	300		400
Income tax expenses (benefit), Total	$ 300		$ 400

Taxes on Income (Details 2) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details 2) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Schedule of reconciliation of income taxes
Loss before income taxes as reported in the consolidated statement of comprehensive loss	$ (14,055)	$ (12,727)	$ (10,080)
Statutory tax benefit	(2,952)	(2,673)	(3,528)
Increase in income taxes resulting from:
Change in the balance of the valuation allowance for deferred tax	3,356	1,583	2,080
Disallowable deductions	86	112	327
Influence of different tax rate applicable to the Subsidiary and changes in tax rates from previous years	(490)	978	1,121
Withholding tax, see note 10d above	300		400
Taxes on income for the reported year	$ 300		$ 400

Taxes on Income (Details Textual) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details Textual) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Taxes on income (Textual)
Accumulated tax loss carryforward	$ 14,336	$ 12,053
Net loss carryforward will expire years, Description	After one year through two years.	After one year through two years.
Taxes on income	$ 300		$ 400
Domestic Tax Authority [Member]
Taxes on income (Textual)
Corporate tax rate	21.00%
Accumulated tax loss carryforward	$ 12,053	$ 12,053
Carryforward tax losses expire	20 years
Net loss carryforward will expire years, Description	Expire in the years 2026 through 2038.
Domestic Tax Authority [Member] \| Minimum [Member]
Taxes on income (Textual)
Corporate tax rate	21.00%
Domestic Tax Authority [Member] \| Maximum [Member]
Taxes on income (Textual)
Corporate tax rate	35.00%
Israel Tax Authority [Member]
Taxes on income (Textual)
Corporate tax rate	23.00%	23.00%	24.00%
Accumulated tax loss carryforward	$ 44,469	$ 134,695
Net loss carryforward will expire years, Description	2013 through 2018.

Related Parties - Transactions (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2019	Jul. 02, 2019	Aug. 31, 2018	Aug. 31, 2017
Related Parties Transactions (Textual)
Directors fees	$ 100		$ 100	$ 100
KNRY [Member]
Related Parties Transactions (Textual)
Consulting agreements, description		The Consulting Agreements are both terminable by either party upon 140 days, prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($36) and NIS 80,454 ($23), respectively.
Chief Executive Officer [Member]
Related Parties Transactions (Textual)
Monthly consulting fee	127,570
Relocation expenses	479
Chief Scientific Officer [Member]
Related Parties Transactions (Textual)
Monthly consulting fee	$ 80,454

Long-Term Deposits and Investment (Details Textual)	12 Months Ended
Long-Term Deposits and Investment (Details Textual)	Aug. 31, 2019
Long Term Deposits (Textual)
Maturity date	Aug. 31, 2020
Minimum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	1.80%
Maximum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	3.44%

Subsequent Events (Details) - Subsequent Events [Member]	Sep. 11, 2019 shares
Subsequent Events (Textual)
Purchase aggregate shares of common stock	100,000
Subsequent events, description	6,250 of such options vested on November 1, 2019 and the remaining 93,750 of such options vest in 15 consecutive equal installments of 6,250 options on the first day of every three month period thereafter. Such officer was granted additional options to purchase 100,000 shares of the Company's common stock at an exercise price of $3.69 per share.
Options expire date	On September 11, 2029.

Taxes on Income (Details 3) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details 3) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Schedule of unrecognized tax benefits activity
Balance at Beginning of Year	$ 11	$ 11	$ 11
Decrease in uncertain tax positions for the current year
Balance at End of Year	$ 11	$ 11	$ 11

Taxes on Income (Details 4) - USD ($) $ in Thousands	12 Months Ended
Taxes on Income (Details 4) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Allowance in respect of carryforward tax losses:
Balance at beginning of period	$ 12,882	$ 11,299	$ 9,219
Additions	3,356	1,583	2,080
Balance at end of period	$ 16,238	$ 12,882	$ 11,299

Related Parties - Transactions (Details) - USD ($) $ in Thousands	Aug. 31, 2019	Aug. 31, 2018
Accounts payable and accrued expenses - KNRY	$ 64	$ 46
KNRY [Member]
Accounts payable and accrued expenses - KNRY	46	46
Accounts payable and accrued expenses - CEO (relocation)		$ 23